Pharvaris Announces Changes to its Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary
To help celebrate GEN’s 40th Anniversary with this special October issue, we asked scientists and business professionals in academia and industry to give us their reflections, impressions, and insights on the biotechnology industry and the life sciences.
Share:
ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) Pharvaris (NASDAQ:PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the presentation of clinical data supporting the multiple-dose safety and pharmacokinetic (PK) profile of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, being held virtually from July 10-16, 2021.
The double-blind, randomized, placebo-controlled, multiple ascending dose study included 38 male and female healthy volunteers. PHA121 was orally administered after standardized meals twice daily (BID) for 10 days in four sequential dosing cohorts, ranging from 12 to 50 mg, with safety and PK assessments during treatment and follow-up for 72 hours after the
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.